Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Impact of Different Selectivity between Soluble and Membrane-bound Forms of Carcinoembryonic Antigen (CEA) on the Target-mediated Disposition of Anti-CEA Monoclonal Antibodies.

Iwano J, Shinmi D, Masuda K, Murakami T, Enokizono J.

Drug Metab Dispos. 2019 Nov;47(11):1240-1246. doi: 10.1124/dmd.119.088179. Epub 2019 Sep 18.

2.

In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors.

Sasayama Y, Hasegawa M, Taguchi E, Kubota K, Kuboyama T, Naoi T, Yabuuchi H, Shimai N, Asano M, Tokunaga A, Ishii T, Enokizono J.

J Control Release. 2019 Sep 7. pii: S0168-3659(19)30537-1. doi: 10.1016/j.jconrel.2019.09.004. [Epub ahead of print]

PMID:
31505222
3.

Pharmacokinetic evaluation of liposomal nanoparticle-encapsulated nucleic acid drug: A combined study of dynamic PET imaging and LC/MS/MS analysis.

Mukai H, Hatanaka K, Yagi N, Warashina S, Zouda M, Takahashi M, Narushima K, Yabuuchi H, Iwano J, Kuboyama T, Enokizono J, Wada Y, Watanabe Y.

J Control Release. 2019 Jan 28;294:185-194. doi: 10.1016/j.jconrel.2018.12.006. Epub 2018 Dec 7.

PMID:
30529725
4.

Development and evaluation of a novel antibody-photon absorber conjugate reveals the possibility of photoimmunotherapy-induced vascular occlusion during treatment in vivo.

Isoda Y, Piao W, Taguchi E, Iwano J, Takaoka S, Uchida A, Yoshikawa K, Enokizono J, Arakawa E, Tomizuka K, Shiraishi Y, Masuda K.

Oncotarget. 2018 Jul 31;9(59):31422-31431. doi: 10.18632/oncotarget.25831. eCollection 2018 Jul 31.

5.

Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigen.

Shinmi D, Nakano R, Mitamura K, Suzuki-Imaizumi M, Iwano J, Isoda Y, Enokizono J, Shiraishi Y, Arakawa E, Tomizuka K, Masuda K.

Cancer Med. 2017 Apr;6(4):798-808. doi: 10.1002/cam4.1003. Epub 2017 Feb 17.

6.

One-Step Conjugation Method for Site-Specific Antibody-Drug Conjugates through Reactive Cysteine-Engineered Antibodies.

Shinmi D, Taguchi E, Iwano J, Yamaguchi T, Masuda K, Enokizono J, Shiraishi Y.

Bioconjug Chem. 2016 May 18;27(5):1324-31. doi: 10.1021/acs.bioconjchem.6b00133. Epub 2016 Apr 28.

PMID:
27074832
7.

Effect of antigen-dependent clearance on pharmacokinetics of anti-heparin-binding EGF-like growth factor (HB-EGF) monoclonal antibody.

Kasai N, Yoshikawa Y, Enokizono J.

MAbs. 2014;6(5):1220-8. doi: 10.4161/mabs.29792. Epub 2014 Nov 1.

8.

Soluble heparin-binding EGF-like growth factor (HB-EGF) detected by newly developed immuno-PCR method is a clear-cut serological biomarker for ovarian cancer.

Kasai N, Kobayashi K, Shioya S, Yoshikawa Y, Yotsumoto F, Miyamoto S, Mekada E, Enokizono J.

Am J Transl Res. 2012;4(4):415-21. Epub 2012 Oct 10.

9.

[Assessment of protein binding].

Enokizono J.

Nihon Yakurigaku Zasshi. 2009 Aug;134(2):78-81. Japanese. No abstract available.

PMID:
19672002
10.

Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds.

Enokizono J, Kusuhara H, Ose A, Schinkel AH, Sugiyama Y.

Drug Metab Dispos. 2008 Jun;36(6):995-1002. doi: 10.1124/dmd.107.019257. Epub 2008 Mar 5.

PMID:
18322075
11.

Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens.

Enokizono J, Kusuhara H, Sugiyama Y.

Mol Pharmacol. 2007 Oct;72(4):967-75. Epub 2007 Jul 20.

PMID:
17644650
12.
13.

Novel 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran derivatives as selective alpha(2C)-adrenergic receptor antagonists.

Hagihara K, Kashima H, Iida K, Enokizono J, Uchida S, Nonaka H, Kurokawa M, Shimada J.

Bioorg Med Chem Lett. 2007 Mar 15;17(6):1616-21. Epub 2007 Jan 25.

PMID:
17257841
15.

Effects of calcium and calcium chelators on growth and morphology of Escherichia coli L-form NC-7.

Onoda T, Enokizono J, Kaya H, Oshima A, Freestone P, Norris V.

J Bacteriol. 2000 Mar;182(5):1419-22.

16.

Structural basis of the interaction between IgG and Fcgamma receptors.

Kato K, Sautès-Fridman C, Yamada W, Kobayashi K, Uchiyama S, Kim H, Enokizono J, Galinha A, Kobayashi Y, Fridman WH, Arata Y, Shimada I.

J Mol Biol. 2000 Jan 14;295(2):213-24.

PMID:
10623521
17.

NMR analysis of the interaction between protein L and Ig light chains.

Enokizono J, Wikström M, Sjöbring U, Björck L, Forsén S, Arata Y, Kato K, Shimada I.

J Mol Biol. 1997 Jul 4;270(1):8-13.

PMID:
9231896

Supplemental Content

Loading ...
Support Center